News
07-09-2010, 04:11 AM
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced that a third multi-center Phase 3 clinical study of Lymphoseek® (NEO3-09) has received investigational review board approval and begun enrollment of subjects diagnosed with breast cancer or melanoma...
More... (http://mnt.to/f/3FSM)
More... (http://mnt.to/f/3FSM)